Flynn, Daniel L. et al. published their patent in 2013 |CAS: 1012882-90-4

The Article related to preparation heterocyclic urea derivative kinase inhibitor treatment myeloproliferative disease, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.Recommanded Product: 1012882-90-4

On March 14, 2013, Flynn, Daniel L.; Petillo, Peter A.; Kaufman, Michael D. published a patent.Recommanded Product: 1012882-90-4 The title of the patent was Preparation of heterocyclic urea derivatives as kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases. And the patent contained the following:

Compounds of the invention (I, wherein E1 is substituted phenyl; A is substituted pyrazolyl and imidazolyl; X2 is a direct bond, wherein E1 is directly linked to the NH group; X3 is -O-; Z6 is independently and individually selected from H, C1-6 alkyl, branched C3-7 alkyl, hydroxy, etc.; t = 1-3) find utility in the treatment of of cancer, secondary cancer growth arising from metastasis, hyperproliferative diseases, diseases characterized by hyper-vascularization, inflammation, osteoarthritis, respiratory diseases, stroke, systemic shock, immunol. diseases, autoimmune diseases, bone resorptive diseases, cardiovascular disease and diseases characterized by angiogenesis. The invention also provides a method of modulating a kinase activity of a wild-type kinase species, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs of any of the foregoing, by contacting said species with a compound I. Synthetic procedures for preparing I are exemplified. Thus, e.g., II was prepared by coupling of 2,2,2-trichloroethyl 3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-ylcarbamate (preparation given) with 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide (preparation given). Assays were described for evaluating binding of I to various kinases, e.g., II demonstrated an IC50 value of 4 nM in the p-Abl kinase assay. The experimental process involved the reaction of Ethyl 5-chloro-2-iodobenzoate(cas: 1012882-90-4).Recommanded Product: 1012882-90-4

The Article related to preparation heterocyclic urea derivative kinase inhibitor treatment myeloproliferative disease, Aliphatic Compounds: Ureas, Carbamic Acids, Guanidines, and Their Sulfur-Containing Analogs and other aspects.Recommanded Product: 1012882-90-4

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com